Autopsy report · NCT01256580

Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD

“Lack of eligible subjects.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Massachusetts Eye and Ear Infirmary

Sponsor type

University, hospital or other

Conditions

Choroidal Neovascularization; Myopia; Punctate Inner Choroidopathy (PIC); Multifocal Choroiditis; Ocular Histoplasmosis Syndrome; Central Serous Chorioretinopathy (CSC)

Interventions

Bevacizumab (Avastin; Genentech, Inc.); Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy

Participants

0

Trials that died the same way

• Nitrite Infusion in Islet Cell Transplantation
  “Lack of eligible subjects, lack of staffing” (85% match in meaning)
• A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH
  “Lack of subjects.” (83% match in meaning)
• Low Dose IV Dexamethasone in Prolonging Caudal Anesthesia in Children Undergoing Genitourinary Surgery
  “Lack of enrollment/lack of potential subjects fitting criteria” (82% match in meaning)
• Project 1: ACHIEVE- HTN
  “Due lack of eligible participants” (81% match in meaning)
• Effect of Externally Implantable Tissue Expansion Device on Scar Length
  “Inability to recruit eligible subjects” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.